Anti-cancer agent and cancer cell killing method
US10030039B2 · kind B2 · utility
Assignees
Inventors
Key dates
| Filing date | Mar 24, 2017 |
| Grant date | Jul 24, 2018 |
| Priority date | — |
| Expiry date | Mar 24, 2037 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P35/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
[Object] An anticancer agent capable of continuously killing cancer cells in a plurality of phases is provided.[Solution] An anticancer agent contains a complex produced by making a metal-salen complex compound, which includes a central metal and (N, N, O, O) as a quadridentate ligand and is magnetic, bind to taxane molecules which are anticancerous; and the anticancer agent is to kill cancer cells regarding which phase transition of its cell cycle occurs between phases including Gap1, Synthesis, Gap2, and Mitosis and Cytokinesis. The present disclosure is suited for use to kill cancer cells of breast cancer and, particularly, cancer cells of triple-negative breast cancer. The present disclosure is designed to make the anticancer agent contact the cancer cells in two or more continuous phases selected from a group consisting of Gap1, Synthesis, Gap2, and Mitosis and Cytokinesis and kill the cancer cells.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.